Recent research reveals the crucial role microRNAs (miRNAs) in the pathogenesis and progression of many pathological conditions, including cardiovascular diseases. It is widely documented that miRNAs represent critical regulators of cardiovascular function and participate in almost all aspects of cardiovascular biology. In particular, they are involved in several pathophysiological pathways of various manifestations of cardiovascular disease, such as coronary artery disease, heart failure, stroke, diabetes mellitus, arterial hypertension and cardiac arrhythmias. In the present article we review the available literature regarding to the role of miRNAs in certain cardiovascular conditions. Moreover, we discuss the therapeutic potential of miRNAs for treating cardiovascular diseases and we attempt to highlight future directions.
Keywords: microRNAs, cardiovascular disease, therapy, atherosclerosis.
Evidence of Lifestyle Modification in the Management of Hypercholesterolemia
Current Cardiology Reviews Alterations in Plasma Triglyceride Concentrations Following Two Oral Meals with Different Fat Content in Patients with Type 2 Diabetes Mellitus
Current Vascular Pharmacology Cardiac and Metabolic Consequences of Aerobic Exercise Training in Experimental Diabetes
Current Diabetes Reviews Molecular Remodeling of the Insulin Receptor Pathway by Thiazolidinediones in Type 2 Diabetes Mellitus: A Brief Review
Protein & Peptide Letters Pharmacology and Chemistry of Diabetes mellitus and Antidiabetic Drugs: A Critical Review
Current Medicinal Chemistry Polycystic Ovary Syndrome as a Proinflammatory State: The Role of Adipokines
Current Pharmaceutical Design Diabetogenic Effects of Parthinium hysterophorous Induced Allergic Rhinitis
Inflammation & Allergy - Drug Targets (Discontinued) Targeting Transient Receptor Potential Channels in Cardiometabolic Diseases and Myocardial Ischemia Reperfusion Injury
Current Drug Targets Global View on Alzheimer’s Disease and Diabetes Mellitus: Threats, Risks and Treatment Alzheimer’s Disease and Diabetes Mellitus
Current Alzheimer Research Vildagliptin Restores Renal Myogenic Function and Attenuates Renal Sclerosis Independently of Effects on Blood Glucose or Proteinuria in Zucker Diabetic Fatty Rat
Current Vascular Pharmacology Riboregulators and Metabolic Disorders: Getting Closer Towards Understanding the Pathogenesis of Diabetes Mellitus?
Current Molecular Medicine Psoriasis and Vascular Risk : An Update
Current Pharmaceutical Design Role of Insulin Signaling in the Interaction Between Alzheimer Disease and Diabetes Mellitus: A Missing Link to Therapeutic Potential
Current Aging Science Medial Vascular Calcification in Diabetes Mellitus and Chronic Kidney Disease: The Role of Inflammation
Cardiovascular & Hematological Disorders-Drug Targets Glucagon Like Peptide-1 and Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Should Cushing’s Syndrome be Considered as a Disease with High Cardiovascular Risk in Relevant Guidelines?
Current Vascular Pharmacology Identification of Novel Pancreatic Lipase Inhibitors Using <i>In Silico</i> Studies
Endocrine, Metabolic & Immune Disorders - Drug Targets Hormonal Effects on Drug Metabolism Through the CYP System: Perspectives on Their Potential Significance in the Era of Pharmacogenomics
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Choosing a Revascularization Strategy in Patients with Diabetes and Stable Coronary Artery Disease: A Complex Decision
Current Cardiology Reviews Beneficial Effects of Vildagliptin on Metabolic Parameters in Patients with Type 2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets